Verywell Health on MSN10mon
Evenity vs. Prolia: Which Is Better for Osteoporosis?
Osteoporosis is a common bone disease characterized by the progressive loss of bone mass and bone density. Osteoporosis ...
pharmaphorum5y
CHMP says no to Amgen’s osteoporosis drug Evenity
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has decided it cannot approve Evenity (romosozumab), issuing a negative opinion on the drug for the treatment of severe ...
pharmaphorum5y
At long last, Amgen/UCB score FDA okay for Evenity
Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...
2AMGN : Amgen's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
Seeking Alpha1mon
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Among these segments, general medicine outperformed, with Repatha and Evenity delivering the strongest growth. The former drug represents a new approach to cardiovascular health (lowering LDL ...